Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Encore Therapeutics has reported that it has created a proprietary nano-emulsion intravenous formulation of progesterone that is suitable for the treatment of stroke and traumatic brain Injury.
Subscribe to our email newsletter
The protective effect of progesterone in treating brain injury has been firmly established but the inability to develop a product that can be used in the field by medical first responders and the absence of intellectual property covering a composition of progesterone have prohibited commercialization.
To address these deficiencies, Encore has developed ETI-411, a novel lyophilized, easy to reconstitute and administer IV progesterone formulation. The company is now seeking a development and commercialization partner to bring ETI-411 to market.
ETI-411 is based on a proprietary phospholipid nano-emulsion formulation that is composed entirely of natural or generally regarded as safe components.
Andrew Chen, chief scientific officer and inventor of the formulation said: “ETI-411 is a substantial improvement over the current means of delivering IV progesterone. It is supplied in a stable, lyophilized format that can be easily reconstituted and administered, making it ideal for first responders and ER personnel treating stroke and traumatic brain Injury victims.”